Skip to main content
Clinical Trials/NCT04669184
NCT04669184
Unknown
Not Applicable

Assessment of Sarcopenia, Physical Performance and Cognitive Function in Hemodialysis Patients

Hacettepe University0 sites26 target enrollmentJanuary 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
End Stage Kidney Disease
Sponsor
Hacettepe University
Enrollment
26
Primary Endpoint
Sarcopenia
Last Updated
5 years ago

Overview

Brief Summary

Many systems such as the cardiovascular, pulmonary, musculoskeletal, hematological, immunological, gastrointestinal, central nervous system are affected due to decreased kidney function. The aim of this study was to investigate the relationship between physical performance and sarcopenia, peripheral muscle strength, activities of daily living, cognitive functions, physical activity level, fragility, pain in hemodialysis patients.

Detailed Description

A high prevalence of sarcopenia has been reported in end stage kidney disease. The incidence of sarcopenia increases with age. Muscle atrophy is caused by an imbalance between the anabolic and catabolic processes in chronic kidney disease. Sarcopenia and physical inactivity progress synergistically. Decreased physical performance is associated with sarcopenia. In hemodialysis patients, daily physical activity level and physical performance decrease. Cognitive impairment is common in chronic kidney disease. Uremic toxins can cause a decrease in cognitive function. One of the most important problems associated with hemodialysis is pain and pain negatively affects functional capacity and quality of life.

Registry
clinicaltrials.gov
Start Date
January 1, 2021
End Date
March 1, 2022
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Merve Firat

Principal Investigator

Hacettepe University

Eligibility Criteria

Inclusion Criteria

  • Having been diagnosed with end stage kidney disease
  • Receiving hemodialysis for more than 3 months
  • Being clinically stable
  • Volunteering to participate in the research

Exclusion Criteria

  • Having an orthopedic disease that may affect functional capacity
  • Having cardiac event in the past 3 months

Outcomes

Primary Outcomes

Sarcopenia

Time Frame: 5 minutes

Sarcopenia will be evaluated using SARC-F questionnaire. For SARC-F, a total score of ≥ 4 indicates sarcopenia.

Physical performance will be evaluated using Short physical performance battery.

Time Frame: 10 minutes

The total score of Short physical performance battery ranges from 0 to 12.

Physical performance will be evaluated using 1 minute sit to stand test.

Time Frame: 5 minutes

1 minute sit to stand test, the maximum number of repetitions within the established time was recorded

Pain level

Time Frame: 5 minutes

Pain will be evaluated using Short-form McGill Pain questionnaire

Secondary Outcomes

  • Peripheral muscle strength(5 minutes)
  • Physical activity level(5 minutes)
  • Activities of daily living(10 minutes)
  • Cognitive function(10 minutes)
  • Fragility(5 minutes)

Similar Trials